Navigation Links
GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners
Date:3/5/2009

SCHLIEREN, Switzerland, March 5 /PRNewswire/ --

- Proceeds to Facilitate Clinical Development of Lead Conjugate Vaccine

GlycoVaxyn, a pioneer in the development of innovative conjugated vaccines, today announced the successful closing of a CHF25 million (ca. US$22 million, EUR17 million) Series B financing. The round was led by Edmond de Rothschild Investment Partners. Existing investors, Index Ventures and Sofinnova Partners, expressed their commitment to the future of the company through significant participation in this round.

Conjugated vaccines provide protection against a growing range of life-threatening bacterial infections. GlycoVaxyn has developed a proprietary technology that allows the engineering of a new type of conjugate vaccine, glycoconjugates. This innovation will enable GlycoVaxyn to address significant unmet medical needs in both industrialized and emerging countries.

The new funds will be used to advance the company's lead vaccine candidate for intestinal infections (Shigellosis), which can cause a major public health issue, into clinical development within the next 12 months. GlycoVaxyn also aims to reach key milestones in its Staphylococcus aureus, Group B meningococcal and Group A Streptococcus conjugate vaccine programs.

In conjunction with the financing, Gilles Nobecourt, Partner at Edmond de Rothschild Investment Partners, has joined GlycoVaxyn's Board of Directors. Of the transaction, he said: "After reviewing several investment opportunities in the field, Edmond de Rothschild Investment Partners has come to the conclusion that GlycoVaxyn has currently one of the most powerful new technology platforms, which has delivered several very promising vaccine candidates. The Company now has sufficient funds to move to the next, clinical stage in its development. I look forward to contribute to the future growth of this company as a Board member."

"Under the leadership of CEO Philippe Dro, GlycoVaxyn has established the solid fundamentals required to raise funding in the current economic downturn," noted Michel Greco, Chairman of GlycoVaxyn. "The company is well financed for the move into clinical trials and as the team continues to deliver on its business strategy, we look forward to the additional support from our new Board member, Gilles."

About GlycoVaxyn

GlycoVaxyn has built a broad portfolio of novel conjugate vaccines against common severe bacterial infections based on its unique, proprietary in-vivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a simplified biological process that circumvents many of the difficulties involved in current methods. The lead conjugate vaccines in development are directed against Shigella dysenteriae, to prevent serious intestinal infections, and against hospital acquired Staphylococcus aureus. GlycoVaxyn also has active programs against N. meningitidis and Group A Streptococcus. GlycoVaxyn, a spin-out of the Swiss Federal Institute of Technology (ETH), is based in Schlieren, near Zurich, Switzerland. For further information, visit http://www.glycovaxyn.com.


'/>"/>
SOURCE GlycoVaxyn AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Eiger BioPharmaceuticals Raises $7.1 Million A Round
2. NanoBio Corporation Raises $12 Million in Series B Financing
3. Divergence Raises $11.8 Million in Series C Financing
4. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
5. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
6. JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism
7. Anacor Raises $50 Million in Equity Financing
8. MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile
9. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
10. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
11. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
Breaking Biology Technology:
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):